Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU) announced that its GSK-3β inhibitor elraglusib was selected for evaluation in the European BEACON2 multi-arm, multi-stage Phase 1/2 trial for relapsed and refractory pediatric neuroblastoma. The regimen combines elraglusib with dinutuximab beta plus chemotherapy and includes an initial dose-confirmation cohort of up to 20 patients, with potential expansion to a randomized stage enrolling about 75 patients.
Rationale includes preclinical data where 60% of Th-MYCN mice receiving elraglusib plus TEMIRI/14G2a remained tumor-free at one year versus 0% for TEMIRI/14G2a alone, a complete bone marrow response in a heavily pretreated neuroblastoma patient, and FDA Rare Pediatric Disease designation for neuroblastoma.
AI-generated analysis. Not financial advice.
Positive
- Elraglusib selected for BEACON2 Phase 1/2 neuroblastoma platform trial
- Dose-confirmation cohort of up to 20 patients with option to expand
- Potential randomized BEACON2 stage enrolling approximately 75 patients
- Preclinical combo data: 60% vs 0% tumor-free Th-MYCN mice at one year
- Phase 1/2 study reported a complete bone marrow response in a neuroblastoma patient
- Elraglusib received FDA Rare Pediatric Disease designation for neuroblastoma
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed peer action (e.g., NVCT up 6.37%, NKTX down 3.33%) with no clear, coordinated move across oncology peers, pointing to a more stock-specific backdrop for ACTU.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Clinical data update | Positive | -1.5% | ASCO 2026 Phase 2 elraglusib data in first-line metastatic pancreatic cancer. |
| May 11 | Regulatory clearance | Positive | -9.8% | FDA IND clearance for oral elraglusib and strategic program advancements. |
| May 06 | Management change | Positive | -2.6% | Appointment of experienced oncology developer Martin Huber to the board. |
| Apr 14 | Clinical trial results | Positive | +14.3% | Nature Medicine publication showing improved survival with elraglusib combo in mPDAC. |
| Mar 24 | Program and PRV update | Positive | -9.4% | Pediatric progress, complete responses, and potential Priority Review Voucher value. |
Recent positive elraglusib updates have more often been followed by negative price reactions, with only one clearly aligned upside move in the last five events.
Over the past six months, Actuate has repeatedly released favorable data and regulatory updates for elraglusib, including Nature Medicine Phase 2 results in mPDAC on Apr 14, 2026 and FDA IND clearance for an oral formulation on May 11, 2026. Despite fundamentally positive narratives, four of the last five news events saw negative 24-hour price reactions. Today’s BEACON2 pediatric neuroblastoma inclusion continues the theme of expanding elraglusib’s clinical footprint into high-need oncology settings.
Regulatory & Risk Context
The company has an active Form S-3 shelf filed on 2025-09-02, with at least two prior takedowns via 424B5 prospectus supplements in September 2025. The shelf is currently not marked effective in the context data, but its presence, alongside existing ATM and equity facilities disclosed in recent filings, indicates management has tools available for future capital raises.
Market Pulse Summary
This announcement underscores further validation for elraglusib, adding BEACON2 evaluation in high-risk pediatric neuroblastoma alongside earlier adult and pediatric data. Preclinical results, such as 60% of Th-MYCN mice remaining tumor-free versus 0% in controls with P<0.0001, support the rationale for combination therapy. Recent filings highlight a limited cash runway and reliance on capital-raising tools, so monitoring trial execution, additional data readouts, and funding developments will be important for assessing ongoing program strength.
Key Terms
gsk-3β medical
pharmacokinetics (pk) medical
cd4+ t cells medical
cd8+ t cells medical
nk cells medical
maximum tolerated dose (mtd) medical
recommended phase 2 dose (rp2d) medical
AI-generated analysis. Not financial advice.
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma
CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that elraglusib will be evaluated in the BEACON2 clinical trial, an international, multi-arm, multi-stage platform study designed to identify and advance promising treatment approaches for children with relapsed and refractory neuroblastoma.
Under the BEACON2 trial design, the combination of elraglusib with dinutuximab beta plus chemotherapy will initially be assessed in a dose confirmation cohort of up to 20 patients to evaluate safety and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) profile of the regimen. Following successful completion of the dose confirmation stage, the regimen may advance into a randomized portion of the platform trial, where approximately 75 patients will be enrolled with a planned interim analysis.
“Selection for inclusion in BEACON2 represents a defining milestone for the elraglusib program and underscores growing recognition of its novel mechanism and potential applicability in treating pediatric cancers,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “Neuroblastoma remains one of the most devastating diseases for many children whose cancer relapses or becomes resistant to treatment, and we are honored to be part of a collaborative effort dedicated to improving outcomes of these patients. BEACON2 is sponsored by the Cancer Research UK Clinical Trials Unit, University of Birmingham, enabling us to generate meaningful clinical data in a capital-efficient manner. We are particularly encouraged by the convergence of compelling preclinical evidence, early clinical evidence in pediatric cancer, including a complete response achieved in a neuroblastoma patient, and regulatory recognition through FDA Rare Pediatric Disease Designation. Together, these factors provide a strong foundation for further exploring the potential of elraglusib in this area of significant unmet medical need.“
Scientific Rationale
The scientific rationale for evaluating elraglusib in neuroblastoma is firmly supported by a growing body of preclinical and clinical evidence. GSK-3β inhibition, elraglusib’s primary mechanism, has been shown to suppress neuroblastoma cell proliferation, promote apoptosis, and disrupt pathways involved in MYCN-driven disease biology, a key driver of high-risk neuroblastoma. Preclinical studies demonstrated that elraglusib enhanced the activity of both chemotherapy and anti-GD2-based immunotherapy, producing significant improvements in tumor control and survival across multiple neuroblastoma models. Notably,
Clinical findings further support the development in neuroblastoma. In the Phase 1/2 (NCT04239092) study of elraglusib in combination with cyclophosphamide plus topotecan chemotherapy, patients with advanced relapsed or refractory disease achieved clinical responses or disease control. Importantly, a heavily pretreated neuroblastoma patient with a high-risk molecular profile achieved a complete bone marrow response within 9 cycles.
About BEACON2
BEACON2 (EudraCT 2024-516115-24) is an international, open-label, multi-arm, multi-stage randomized Phase 1/2 trial evaluating multiple treatment regimens aimed at identifying treatment approaches that will lead to improved outcomes. BEACON2 is being conducted by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, one of the most respected academic clinical trials organizations in the world and one of only eight units directly funded by Cancer Research UK, the UK's largest cancer research charity. The trial is currently active across 14 UK sites and has received European regulatory approval via CTIS, with an international network spanning up to 60 sites across 16 countries, including the European Union, UK, Switzerland, Israel, Australia, and New Zealand.
BEACON2 builds on the original BEACON trial, which established a pan-European platform for evaluating and comparing treatment regimens in relapsed and refractory neuroblastoma. Conducted between 2012 and 2021, BEACON enrolled 225 patients across Europe, making it the largest randomized clinical trial ever conducted in this patient population. The study successfully identified two combination regimens worthy of further investigation, including irinotecan and temozolomide and dinutuximab beta administered with a chemotherapy backbone, which demonstrated one-year progression-free survival rates of
About Neuroblastoma
Neuroblastoma is a rare pediatric cancer that develops from immature nerve cells and remains associated with persistently poor outcomes following relapse. Despite advances in frontline therapy, treatment options remain limited for patients whose disease recurs or becomes resistant to treatment, highlighting the need for new therapeutic approaches.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward Looking Statements
This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond July 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
